Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability?

Journal of Urology

Volumn 160, Issue 3 I, 1998, Pages 784-791

  Michel, Martin C ^a   Mehlburger, Ludwig ^b   Bressel, Hans Ulrich ^b   Schumacher, Helmut ^b   Schäfers, Rafael F ^b   Goepel, Mark ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

Benign; Comorbidity; Prostatic hypertrophy; Urinary tract

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; TAMSULOSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

EID: 0032324359     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62787-3     Document Type: Article

References (32)

1. Khoury, A. F. and Kaplan, N. M.: Alpha-blocker therapy of hypertension. An unfulfilled promise. J.A.M.A., 266: 394, 1991.
2. van Zwieten, P. A.: α-Adrenoceptor blocking agents in the treatment of hypertension. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. Edited by J. H. Laragh and B. M. Brenner, New York: Raven Press, chapt. 175, pp. 2917-2935, 1995.
3. Oesterling, J. E.: Benign prostatic hyperplasia. Medical and minimally invasive treatment options. New Engl. J. Med., 332: 99, 1995.
4. Eri, L. M. and Tveter, K. J.: α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol., 154: 923, 1995.
5. Gee, W. F., Holtgrewe, H. L., Albertsen, P. C., Litwin, M. S., Manyak, M. J., O'Leary, M. P. and Painter, M. R.: Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J. Urol., 154: 205, 1995.
6. Carruthers, S. G.: Adverse effects of alpha 1-adrenergic blocking drugs. Drug Safety, 11: 12, 1994.
7. Kirby, R. S.: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology, 46: 182, 1995.
8. Lukacs, B., Leplege, A., Thibault, P. and Jardin, A.: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology, 48: 731, 1996.
9. Michel, M. C., Grübbel, B., Taguchi, K., Verfürth, F., Otto, T. and Kröpfl, D.: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1-adrenoceptor subtypes and in human prostate. J. Auton. Pharmacol., 16: 21, 1996.
10. Wilde, M. I. and McTavish, D.: Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of benign prostatic hyperplasia. Drugs, 52: 883, 1996.
11. Taguchi, K., Schafers, R. F. and Michel, M. C.: Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Brit. J. Clin. Pharmacol., 45: 49, 1998.
12. Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A. F. G. V. M., Abrams, P. and the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur. Urol., 29: 155, 1996.
13. Lepor, H.: Phase III multicenter, placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology, 51: 892, 1998.
14. Cockett, A. T. K., Khoury, S., Aso, Y., Chatelain, C., Denis, L., Griffiths, L. and Murphy, G.: The 2nd International Consultation on Benign Prostatic Hyperplasia. Channel Island: Scientific Communication International Ltd., pp. 624-631, 1994.
15. Motulsky, H. J., Snavely, M. D., Hughes, R. J. and Insel, P. A.: Interaction of verapamil and other calcium channel blockers with α1- and α2-adrenergic receptors. Circ. Res., 52: 226, 1983.
16. Andersson, K. E., Lepor, H. and Wyllie, M. G.: Prostatic α1-adrenoceptors and uroselectivity. Prostate, 30: 202, 1997.
17. Chapple, C. R.: Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur. Urol., 29: 129, 1996.
18. Buzelin, J. M., Fonteyne, E., Kontturi, M. J., Witjes, W. P. J., Khan, A. and the European Tamsulosin Study Group: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Brit. J. Urol., 80: 597, 1997.
19. Lee, E. and Lee, C.: Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Brit. J. Urol., 80: 606, 1997.
20. Chapple, C. R., Carter, P., Christmas, T. J., Kirby, R. S., Bryan, J., Milroy, E. J. and Abrams, P.: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74: 50, 1994.
21. Roehrborn, C. G. and Siegel, R. L.: Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology, 48: 406, 1996.
22. Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Lloyd, L. K., Milam, D. E. and Padley, R. J.: The Hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH). Urology, 47: 159, 1996.
23. Brawer, M. K., Adams, G., Epstein, H. and the Terazosin Benign Prostatic Hyperplasia Study Group: Terazosin in the treatment of benign prostatic hyperplasia. Arch. Fam. Med., 2: 929, 1993.
24. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., Padley, R. J. and the Veterans Affairs Cooperative Benign Prostatic Hyperplasia Study Group: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med., 335: 533, 1996.
25. Jardin, A., Bensadoun, H., Delauche-Cavallier, M. C., Attali, P. and The BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet, 337: 1457, 1991.
26. Buzelin, J. M., Delauche-Cavallier, M. C., Roth, S., Geffriaud-Ricouard, C. and Santoni, J. P.: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Brit. J. Urol., 79: 898, 1997.
27. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K., Dias, N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol., 154: 110, 1995.
28. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K., Dias, N. for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
29. de Planque, B. A.: A double-blind comparative study of doxazosin and prazosin when administered with β-blockers or diuretics. Amer. Heart J., 121: 304, 1991.
30. Englert, R. G. and Barlage, U.: The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by β-blockers. Amer. Heart J., 121: 311, 1991.
31. Lindner, U. K., von Manteuffel, G.-E. and Stafunsky, M.: The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Amer. Heart J., 116: 1814, 1988.
32. Englert, R. G. and Mauersberger, H.: A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Amer. Heart J., 116: 1826, 1988.